Patents by Inventor Jayakrishna Ambati

Jayakrishna Ambati has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190255049
    Abstract: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
    Type: Application
    Filed: March 22, 2019
    Publication date: August 22, 2019
    Inventors: Jayakrishna Ambati, Benjamin Fowler
  • Patent number: 10344095
    Abstract: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
    Type: Grant
    Filed: February 16, 2006
    Date of Patent: July 9, 2019
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati
  • Patent number: 10300057
    Abstract: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
    Type: Grant
    Filed: April 29, 2016
    Date of Patent: May 28, 2019
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Benjamin Fowler
  • Patent number: 10294220
    Abstract: The present disclosure relates to nucleosides, such as compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to nucleosides, such as compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.
    Type: Grant
    Filed: February 26, 2016
    Date of Patent: May 21, 2019
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Benjamin Fowler, Kameshwari Ambati
  • Publication number: 20180044327
    Abstract: The present disclosure relates to compounds, compositions, and methods useful for treating retinal damage and/or retinal degradation/retinal degeneration, for inhibiting inflammasome activation by Alu RNA associated with a cell, for reducing ATP-induced permeability of a cell, for reducing an amount of mitochondrial reactive oxygen species in a cell, and for reducing an amount of mitochondrial reactive oxygen species in a cell. The present disclosure further relates to compounds, compositions, and methods for use in protecting an RPE cell and/or for treating, including prophylactic and therapeutic treatment, of conditions associated with retinal damage and/or degradation including, but not limited to, dry age related macular degeneration (AMD) and wet AMD, Alzheimer disease, various forms of arthritis, atherosclerosis, diabetes mellitus, chronic obstructive pulmonary disease, inflammatory bowel disease, and Duchenne muscular dystrophy.
    Type: Application
    Filed: February 26, 2016
    Publication date: February 15, 2018
    Inventors: Jayakrishna AMBATI, Benjamin FOWLER, Kameshwari AMBATI
  • Patent number: 9707235
    Abstract: Therapeutic uses P2X7 inhibition and inhibition of IRAK1 and/or IRAK4, methods protecting a cell, and screening methods for identifying inhibitors are described herein.
    Type: Grant
    Filed: January 14, 2013
    Date of Patent: July 18, 2017
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati
  • Patent number: 9464289
    Abstract: The presently-disclosed subject matter includes methods of identifying an Alu RNA inhibitor, and methods and compositions for inhibiting Alu RNA. Methods and compositions can be used for the treatment of geographic atrophy and other conditions of interest.
    Type: Grant
    Filed: July 3, 2014
    Date of Patent: October 11, 2016
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati
  • Patent number: 9453226
    Abstract: A method of protecting a cell includes inhibiting an inflammasome, MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NF?B of the cell. Administering an inhibitor of MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NF?B can protect the cell from Alu-RNA-induced degeneration. Protecting a cell, such as an retinal pigment epithelium (RPE), can be therapeutically useful in the context of age-related macular degeneration and geographic atrophy.
    Type: Grant
    Filed: January 17, 2014
    Date of Patent: September 27, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Valeria Tarallo
  • Publication number: 20160263114
    Abstract: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
    Type: Application
    Filed: April 29, 2016
    Publication date: September 15, 2016
    Inventors: Jayakrishna Ambati, Benjamin Fowler
  • Patent number: 9326983
    Abstract: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
    Type: Grant
    Filed: August 1, 2014
    Date of Patent: May 3, 2016
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Benjamin Fowler
  • Publication number: 20160009810
    Abstract: A method of suppressing angiogenesis involves administering to a subject an isolated Fc fragment of an IgG1 antibody, or an IgG1 antibody.
    Type: Application
    Filed: March 13, 2014
    Publication date: January 14, 2016
    Inventor: Jayakrishna AMBATI
  • Patent number: 9198981
    Abstract: This invention relates to compounds, compositions, and methods for the treatment of traits, diseases and conditions that respond to the modulation of angiogenic growth factor bioavailability or biological activity.
    Type: Grant
    Filed: October 17, 2006
    Date of Patent: December 1, 2015
    Assignee: The University of Kentucky
    Inventors: Balamurali Krishna Ambati, Jayakrishna Ambati, Nirbhai Singh
  • Patent number: 8957035
    Abstract: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of stimulators of the TLR3 and TLR7 receptors, Trif or of IL-10 and IL-12 inhibits ocular angiogenesis. Furthermore, all siRNAs (both targeted and non-targeted) can inhibit ocular angiogenesis.
    Type: Grant
    Filed: May 15, 2007
    Date of Patent: February 17, 2015
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati
  • Publication number: 20150038446
    Abstract: The present disclosure relates to compositions and methods for treating retinal damage and/or retinal degradation. More specifically, this disclosure relates to methods for treating degradation of the retinal pigment epithelium by administering compositions comprising a nucleoside and/or a nucleoside or nucleotide reverse transcriptase inhibitor.
    Type: Application
    Filed: August 1, 2014
    Publication date: February 5, 2015
    Inventors: Jayakrishna Ambati, Benjamin Fowler
  • Publication number: 20140342357
    Abstract: The presently-disclosed subject matter includes methods of identifying an Alu RNA inhibitor, and methods and compositions for inhibiting Alu RNA. Methods and compositions can be used for the treatment of geographic atrophy and other conditions of interest.
    Type: Application
    Filed: July 3, 2014
    Publication date: November 20, 2014
    Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventor: Jayakrishna Ambati
  • Patent number: 8846386
    Abstract: Disclosed herein are nucleic acid molecules comprising a nucleotide sequence of sVEGF-2, proteins encoded by those sequences and antibodies that bind to the protein. Also disclosed are methods for inhibiting or enhancing expression or activity of sVEGFR-2 and methods for inhibiting graft rejection, particularly cornea graph rejection. Also described are methods for inhibiting lymphangiogenesis and lymphatic endothelial cell proliferation by administering an effective amount of sVEGFR-2 and methods for treating lymphedema by inhibiting the activity of sVEGFR-2.
    Type: Grant
    Filed: December 18, 2008
    Date of Patent: September 30, 2014
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Rumulo J. C. Albuquerque
  • Patent number: 8809517
    Abstract: The presently-disclosed subject matter includes methods of identifying an Alu RNA inhibitor, and methods and compositions for inhibiting Alu RNA. Methods and compositions can be used for the treatment of geographic atrophy and other conditions of interest.
    Type: Grant
    Filed: June 1, 2011
    Date of Patent: August 19, 2014
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati
  • Patent number: 8778616
    Abstract: The results presented herein demonstrate the specific expression of CCR3 in CNV endothelial cells in humans with AMD, and despite the expression of its ligands, eotaxin-1, -2, and -3, neither eosinophils nor mast cells are present in human CNV. The genetic or pharmacological targeting of CCR3 or eotaxins as disclosed herein inhibited injury-induced CNV in mice. CNV suppression by CCR3 blockade was due to direct inhibition of endothelial cell proliferation, and was uncoupled from inflammation as it occurred in mice lacking eosinophils or mast cells and was independent of macrophage and neutrophil recruitment. CCR3 blockade was more effective at reducing CNV than vascular endothelial growth factor-A (VEGF-A) neutralization, which is currently in clinical use, and, unlike VEGF-A blockade, not toxic to the mouse retina. In vivo imaging with CCR3-targeting quantum dots located spontaneous CNV invisible to standard fluorescein angiography in mice before retinal invasion.
    Type: Grant
    Filed: May 26, 2010
    Date of Patent: July 15, 2014
    Assignee: University of Kentucky Research Foundation
    Inventors: Jayakrishna Ambati, Mark Ellsworth Kleinman
  • Publication number: 20140178309
    Abstract: A method of protecting a cell includes inhibiting an inflammasome, MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NF?B of the cell. Administering an inhibitor of MyD88, IL-18, VDAC1, VDAC2, caspase-8, and/or NF?B can protect the cell from Alu-RNA-induced degeneration. Protecting a cell, such as an retinal pigment epithelium (RPE), can be therapeutically useful in the context of age-related macular degeneration and geographic atrophy.
    Type: Application
    Filed: January 17, 2014
    Publication date: June 26, 2014
    Applicant: UNIVERSITY OF KENTUCKY RESEARCH FOUNDATION
    Inventors: Jayakrishna AMBATI, Valeria TARALLO
  • Patent number: 8592482
    Abstract: Provided are methods and compositions for the treatment or prevention of ocular angiogenesis and neovascularization. Administration of inhibitors of the CCR3 receptor or its ligands eotaxin (CCL11), eotaxin-2 (CCL24) or eotaxin-3 (CCL26) inhibits ocular angiogenesis.
    Type: Grant
    Filed: July 7, 2011
    Date of Patent: November 26, 2013
    Assignee: University of Kentucky Research Foundation
    Inventor: Jayakrishna Ambati